Neuraxis, Inc. (NYSE MKT:NRXS) — Market Cap & Net Worth
Market Cap & Net Worth: Neuraxis, Inc. (NRXS)
Neuraxis, Inc. (NYSE MKT:NRXS) has a market capitalization of $84.91 Million ($84.91 Million) as of September 17, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #19888 globally and #4544 in its home market, demonstrating a -11.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuraxis, Inc.'s stock price $7.38 by its total outstanding shares 11505421 (11.51 Million). Also see Neuraxis, Inc. total assets for a full breakdown of the balance sheet.
Neuraxis, Inc. Market Cap History: 2023 to 2026
Neuraxis, Inc.'s market capitalization history from 2023 to 2026. Data shows growth from $30.72 Million to $84.91 Million (7.71% CAGR). Also see how efficiently does Neuraxis, Inc. generate cash for how efficiently the company converts equity into cash flow.
Neuraxis, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuraxis, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Neuraxis, Inc. stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
14.63x
Neuraxis, Inc.'s market cap is 14.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $30.72 Million | $2.46 Million | -$14.63 Million | 12.49x | N/A |
| 2024 | $27.61 Million | $2.69 Million | -$8.24 Million | 10.28x | N/A |
| 2025 | $52.23 Million | $3.57 Million | -$7.80 Million | 14.63x | N/A |
Competitor Companies of NRXS by Market Capitalization
Companies near Neuraxis, Inc. in the global market cap rankings as of September 17, 2026. Review NRXS tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Neuraxis, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Neuraxis, Inc. Historical Marketcap From 2023 to 2026
Between 2023 and today, Neuraxis, Inc.'s market cap moved from $30.72 Million to $ 84.91 Million, with a yearly change of 7.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $84.91 Million | +62.56% |
| 2025 | $52.23 Million | +89.17% |
| 2024 | $27.61 Million | -10.11% |
| 2023 | $30.72 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Neuraxis, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $84.91 Million USD |
| MoneyControl | $84.91 Million USD |
| MarketWatch | $84.91 Million USD |
| marketcap.company | $84.91 Million USD |
| Reuters | $84.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional … Read more